Voluntary announcement - biologics license application of risvutatug rezetecan for injection (HS-20093) for osteosarcoma accepted by the nmpa
Filed with HKEX · Stock code 3692 · · 1 page · English
Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 3692) VOLUNTARY ANNOUNCEMENT BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR OSTEOSARCOMA ACCEPTED BY THE NMPA The board of directors (the “Board”) of Hansoh Pharmaceutical Group Company Limited (the “Company” and together with its subsi
Hansoh Pharmaceutical Group Company Limited on 6ix
Earlier from Hansoh Pharmaceutical
- Notification letter to non-registered holders and request form
- Notification letter to registered shareholders and reply form
- Interim report 2026
- Voluntary announcement - risvutatug rezetecan for injection (HS-20093) for osteosarcoma included in priority review and approval procedure of the nmpa
- Hansoh Pharmaceutical Group: Pharma announces pivotal phase 3 clinical trial of HS-10374 in the treatment of adults with moderate-to-severe plaque psoriasis met the co-primary endpoints
Later from Hansoh Pharmaceutical
- Voluntary announcement - update on the marketing authorization status of aumolertinib in the EU
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - marketing authorization application of Aumolertinib in the EU resubmitted and validated by the EMA
- Inside information - strategic collaboration and license agreement with roche
Follow Hansoh Pharmaceutical into a list and get an email when it puts out news.
Follow Hansoh Pharmaceutical